Neurogene Inc. Files 8-K: Material Agreement, Other Events
Ticker: NGNE · Form: 8-K · Filed: Apr 14, 2025 · CIK: 1404644
Sentiment: neutral
Topics: material-agreement, corporate-filing, company-name-change
TL;DR
Neurogene filed an 8-K on 4/14/25 for a material agreement. Big news pending.
AI Summary
On April 14, 2025, Neurogene Inc. filed an 8-K report detailing a material definitive agreement. The filing also includes other events and financial statements/exhibits. Neurogene Inc. was formerly known as Neoleukin Therapeutics, Inc., Aquinox Pharmaceuticals, Inc., and Aquinox Pharmaceuticals (USA) Inc.
Why It Matters
This 8-K filing indicates significant corporate activity and potential new agreements for Neurogene Inc., which could impact its strategic direction and financial performance.
Risk Assessment
Risk Level: medium — 8-K filings often signal material events, but the specific nature of the agreement and its financial implications are not detailed in this summary, requiring further investigation.
Key Players & Entities
- Neurogene Inc. (company) — Registrant
- Neoleukin Therapeutics, Inc. (company) — Former company name
- Aquinox Pharmaceuticals, Inc. (company) — Former company name
- Aquinox Pharmaceuticals (USA) Inc (company) — Former company name
- April 14, 2025 (date) — Date of report
FAQ
What is the nature of the material definitive agreement entered into by Neurogene Inc. on April 14, 2025?
The provided text states that an 'Entry into a Material Definitive Agreement' is an item of disclosure in the 8-K filing, but does not specify the details of the agreement itself.
What other events are reported in this 8-K filing by Neurogene Inc.?
The filing indicates 'Other Events' as a reported item, but the specific nature of these events is not detailed in the provided text.
What financial statements and exhibits are included with this 8-K filing?
The filing lists 'Financial Statements and Exhibits' as included, but the specific contents are not detailed in the provided text.
When did Neurogene Inc. change its name from Neoleukin Therapeutics, Inc.?
Neurogene Inc. was formerly known as Neoleukin Therapeutics, Inc., with a date of name change listed as August 12, 2019.
What is Neurogene Inc.'s principal executive office address?
Neurogene Inc.'s principal executive offices are located at 535 W 24th Street, 5th Floor, New York, NY 10011.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 14, 2025 regarding Neurogene Inc. (NGNE).